Mapping the immune landscape in liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses advanced MRI scans and tumor samples to understand how the immune system behaves in liver cancer. It aims to improve personalized treatment by looking at the tumor's environment at different times.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of hepatocellular carcinoma (HCC), the most common type of liver cancer.
- You must be scheduled for surgery, and before that surgery you need to have had a special MRI (called EOB-MRI) within the past month.
- Your tumor must be at least 1 centimeter in size (about the size of a pea).
- You should not have received any other cancer treatments before this surgery.
- Your scans must be of good quality for the study to use them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special MRI scans to learn more about liver cancer (hepatocellular carcinoma) before and during treatment with TACE or SIRT. It may help doctors better understand how the tumor responds to therapy.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.